Physician profile
Eric G Smith
NPI 1689748725
$15,164.40
in general payments reported to CMS, 2019-2025
59 companies · $2,408 in 2025
The $2,408 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,204 · 2020: $818 · 2021: $1,667 · 2022: $2,883 · 2023: $2,571 · 2024: $2,614 · 2025: $2,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,443 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,443.41 |
| Education | $149.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,123.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,741.94 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $1,490.93 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $1,030.91 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $843.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $630.87 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $555.85 | 2019-2025 | Jardiance |
| Grifols USA, LLC | $491.45 | 2019-2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $450.42 | 2019-2023 | Spravato |
| Astrazeneca Pharmaceuticals LP | $411.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $391.02 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $372.46 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Nestle Healthcare Nutrition INC. | $319.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $267.05 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $218.08 | 2022-2025 | Caplyta |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.